NEWARK, Del, March 11, 2025 (GLOBE NEWSWIRE) -- The global branded generics market is set for substantial growth, with sales expected to rise from USD 382.4 billion in 2025 to USD 860.5 billion by 2035, expanding at a CAGR of 8.4% during the forecast period. In 2024, the market generated USD 353.7 billion in revenue, demonstrating a strong upward trajectory.
The growth of branded generics is primarily driven by the loss of patent exclusivity on innovator drugs, enabling pharmaceutical companies to introduce branded generics with strong brand recognition at competitive prices. Additionally, policy incentives, including exclusivity periods for first-to-market generics, have accelerated their adoption across various regions.
Track Evolving Market Trends: Request Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d31323630
Unlike unbranded generics, branded generics benefit from physician confidence, brand loyalty, and targeted marketing efforts, ensuring continued prescription volume. Furthermore, vertical integration and manufacturing efficiencies have allowed pharmaceutical companies to produce cost-effective alternatives while maintaining quality standards.
Another key factor bolstering market growth is the push for cost-containment by health systems and payers, which favors branded generics over expensive originator drugs. Moreover, strategic collaborations and acquisitions are enabling companies to expand their branded generic portfolios, enhance distribution channels, and strengthen their global footprint.
Analysis by Drug Class
The branded generics market is categorized based on various drug classes, each contributing significantly to market expansion.
- Analgesics – Driven by the increasing prevalence of chronic pain conditions and post-surgical pain management, analgesic branded generics are witnessing strong demand.
- Antibiotics – With rising concerns over antimicrobial resistance, pharmaceutical companies are focusing on developing branded generic antibiotics to maintain efficacy while ensuring affordability.
- Cardiovascular Drugs – The growing burden of cardiovascular diseases (CVDs) globally has fueled the demand for cost-effective treatment options, leading to the expansion of branded generic cardiovascular drugs.
- CNS (Central Nervous System) Drugs – With neurological and psychiatric disorders on the rise, branded generics in this category are becoming increasingly essential for long-term patient care.
- Respiratory Drugs – The surge in respiratory conditions such as asthma and COPD has boosted the demand for branded generics in this segment.
Analysis by Therapy Area
Branded generics cater to a wide range of therapy areas, with significant growth projected in the following sectors:
- Oncology – The rising incidence of cancer worldwide is driving the adoption of branded generic oncology drugs, providing affordable treatment options to patients.
- Diabetes Management – With diabetes cases escalating globally, branded generics are bridging the gap between innovation and accessibility in diabetes care.
- Infectious Diseases – The demand for effective and affordable medications in combating infections continues to support the growth of branded generics in this segment.
- Gastrointestinal Disorders – Increased cases of gastrointestinal diseases, including acid reflux and irritable bowel syndrome, are contributing to market expansion.
- Autoimmune Diseases – The growing awareness and diagnosis of autoimmune disorders are propelling the demand for cost-effective branded generics in this category.
"The branded generics market is witnessing a significant transformation, primarily fueled by the wave of patent expirations and supportive policy frameworks. Pharmaceutical firms are leveraging physician trust and brand reputation to maintain market share, even in a competitive generic landscape. The rising emphasis on cost containment by healthcare providers further propels the shift toward branded generics. Moving forward, companies that strategically invest in portfolio expansion and global market penetration through mergers and acquisitions will likely see sustained growth in this space." says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report! https://www.futuremarketinsights.com/reports/branded-generics-market
Key Growth Drivers and Pressing Challenges
Key Drivers:
- Patent Expirations – The continuous expiration of blockbuster drug patents is creating opportunities for branded generics to capture market share.
- Cost-Effectiveness – Branded generics offer a middle ground between costly brand-name drugs and traditional generics, ensuring affordability without compromising quality.
- Regulatory Support – Governments worldwide are promoting branded generics to enhance drug accessibility and reduce healthcare costs.
Challenges:
- Regulatory Hurdles – Stringent regulatory requirements can impact the approval and marketing of branded generics in certain regions.
- Competition from Traditional Generics – The presence of low-cost generic drugs poses a challenge to branded generics' market penetration.
- Physician and Consumer Perception – Overcoming skepticism regarding the efficacy of branded generics remains a crucial aspect of market growth.
Important Developments in the Branded Generics Sector
- India is projected to witness the highest CAGR of 7.6% from 2025 to 2035, indicating strong market expansion.
- China follows closely with a 6.6% CAGR, reflecting significant growth potential in the region.
- South Korea and Japan are expected to grow at 5.7% and 5.2% CAGR, respectively, showcasing steady advancements.
- The United Kingdom (4.3%) and United States (4.1%) anticipate moderate yet consistent market growth.
- Emerging markets in Asia demonstrate higher growth rates compared to Western nations, suggesting increasing industry investments and demand in these regions.
Branded Generics Market Dynamics & Future Trends (2025-2035)
The branded generics market is poised for substantial growth, driven by increasing demand for cost-effective medications, an expanding aging population, and heightened healthcare expenditure. Emerging markets, particularly in Asia-Pacific and Latin America, are expected to witness significant adoption due to favorable regulatory frameworks and rising disease prevalence.
Competition and Market Share in Branded Generics
The branded generics market is highly competitive, with multinational pharmaceutical companies, regional players, and local manufacturers vying for market share. Unlike patented medicines, which enjoy exclusivity, branded generics face challenges from both unbranded generics and competing branded products throughout their patent protection lifecycle. This intensifies competition within the industry.
Market leaders vary by region, with global pharmaceutical giants such as Pfizer, Novartis, and Teva competing alongside strong local players like Sun Pharma in India, Sinopharm in China, and Hanmi Pharmaceutical in South Korea. Foreign companies often face difficulties establishing a strong presence due to domestic firms’ first-mover advantage in regulatory approvals, distribution networks, and physician trust.
Recent Developments in the Branded Generics Market
- June 2024: Teva Pharmaceuticals received FDA authorization for a generic version of Victoza, a medication used to treat Type 2 diabetes.
- June 2024: Canadian pharmaceutical company Apotex Inc. announced the successful acquisition of Searchlight Pharma Inc., a leading player in the Canadian pharmaceutical market.
Advantage Healthcare Insights to Outpace Competitors! https://www.futuremarketinsights.com/industry-analysis/pharmaceuticals
Key Players of Branded Generics Market Industry
- Mylan Pharmaceuticals Inc. (Viatris Inc.)
- Novartis AG
- Teva Pharmaceuticals
- Pfizer Inc.
- Sun Pharmaceutical
- Aspen Pharmacare Holding Ltd.
- Abbott Laboratories
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- GlaxoSmithKline Pharmaceuticals Ltd.
- Zydus Lifesciences Ltd.(CADILA)
- Lupin Pharmaceuticals Inc.
- Sanofi S.A.
- AstraZeneca
- Dr. Reddy’s Laboratories Ltd.
- AbbVie Inc. (Allergan, Inc.)
- Bayer AG
- Cipla Pharmaceuticals
- Apotex Inc.
- Endo International Inc.
Branded Generics Industry Analysis of Key Segments
By Drug class:
- Anti-Hypertensive
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants Anti-Psychotics
- Anti-Epileptics
- Other
By Therapy Area:
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics and Anti-inflammatory
- Others
By Formulation Type:
- Oral
- Parenteral
- Topical
- Others
By Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- East Asia
- South Asia & Pacific
- Western Europe
- Eastern Europe
- Middle East and Africa (MEA)
Explore FMI’s Related Ongoing Coverage on Healthcare Domain:
The super generics market size is estimated to reach the anticipated market value of USD 413 billion by 2033 while expanding its global space at a promising CAGR of 7.2% (2023 to 2033). The market holds a revenue of USD 205 billion in 2023.
The demand for super generics in Europe was valued at USD 11.6 billion in 2023 and is expected to reach USD 14.2 billion by 2033. It is estimated to surge at a CAGR of close to 2.0% over the forecast period from 2023 to 2033.
The global eye care supplement industry share is expanding as more people prioritize vision health. Valued at USD 2,617.2 million in 2025, it is projected to reach USD 4,912.9 million by 2035, growing at a CAGR of 6.5%.
The global radioimmunoassay market growth is forecasted to attain USD 491.6 million by 2025, expanding at 4.4% CAGR to reach USD 752.9 million by 2035. In 2024, the revenue of radioimmunoassay was around USD 470.8 million.
The global biotin supplement market trends is forecasted to attain USD 4,351.0 million by 2025, expanding at 8.5% CAGR to reach USD 9,837.6 million by 2035. In 2024, the revenue of biotin supplement was around USD 4,010.2 million.
The global acetaminophen API market forecast is estimated to be worth USD 1,262.0 million in 2025 and is anticipated to grow at a CAGR of 3.4% to reach USD 1,763.1 million by 2035.
The plant derived analgesics market outlook is estimated to be worth USD 4,262.9 million in 2025 and are anticipated to reach a value of USD 8,575.5 million by 2035. Sales are projected to rise at a CAGR of 7.2% over the forecast period between 2025 and 2035.
The global pharmaceutical lipids market overview is valued at USD 5,492.6 million in 2025, registering Y-o-Y growth of 5.1% attaining market value of USD 9,036.5 million by 2035. The revenue generated by allergy immunotherapy in 2024 was USD 5,209.3 million.
The global sales of generic injectable are estimated to be worth USD 135.4 billion in 2025 and are anticipated to reach a value of USD 401.8 billion by 2035. Sales are projected to rise at a CAGR of 11.5% over the forecast period between 2025 and 2035.
The global drug formulation market analysis are estimated to be worth USD 1.7 trillion in 2025 and are anticipated to reach a value of USD 2.8 trillion by 2035. Sales are projected to rise at a CAGR of 5.7% over the forecast period between 2025 and 2035.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
